Willem Mario Kuhtreiber, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| C-Peptide | 1 | 2015 | 419 | 0.470 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 3 | 2020 | 357 | 0.380 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2015 | 3336 | 0.220 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2020 | 2988 | 0.140 |
Why?
|
| Deoxyglucose | 1 | 2015 | 337 | 0.120 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 3586 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 4560 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 2541 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2020 | 4445 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 8428 | 0.060 |
Why?
|
| Autoantigens | 1 | 2008 | 892 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2020 | 1821 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2015 | 6256 | 0.050 |
Why?
|
| Sezary Syndrome | 1 | 2020 | 76 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2020 | 1095 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4420 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2020 | 1723 | 0.040 |
Why?
|
| Immunoassay | 1 | 2020 | 752 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2020 | 1730 | 0.030 |
Why?
|
| Prognosis | 1 | 2015 | 29063 | 0.030 |
Why?
|
| Cell Death | 1 | 2020 | 1706 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 25043 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1915 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 16689 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3557 | 0.030 |
Why?
|
| Apoptosis | 1 | 2008 | 9727 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 4933 | 0.030 |
Why?
|
| Receptors, Glucagon | 1 | 1992 | 92 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 10180 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 57776 | 0.020 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1994 | 745 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 56430 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8642 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 13815 | 0.020 |
Why?
|
| Child | 1 | 2015 | 77709 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 85781 | 0.020 |
Why?
|
| Gene Expression | 1 | 2020 | 7799 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 11031 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 1992 | 1352 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10481 | 0.020 |
Why?
|
| Mice | 2 | 2020 | 81183 | 0.010 |
Why?
|
| Aged | 1 | 2015 | 163280 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2020 | 21746 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 213383 | 0.010 |
Why?
|
| Adult | 1 | 2015 | 214055 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 5686 | 0.010 |
Why?
|
| Animals | 4 | 2020 | 168757 | 0.010 |
Why?
|
| Humans | 4 | 2020 | 744343 | 0.010 |
Why?
|
| Glucose | 1 | 1992 | 4397 | 0.010 |
Why?
|
| Peptides | 1 | 1992 | 4409 | 0.010 |
Why?
|
| Insulin | 2 | 2008 | 6580 | 0.010 |
Why?
|
| Polyvinyl Chloride | 1 | 1994 | 34 | 0.010 |
Why?
|
| Acrylic Resins | 1 | 1994 | 142 | 0.010 |
Why?
|
| Biopolymers | 1 | 1994 | 189 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 63114 | 0.010 |
Why?
|
| Glucagon-Like Peptides | 1 | 1992 | 127 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1994 | 2505 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1994 | 1402 | 0.010 |
Why?
|
| Dogs | 1 | 1994 | 3912 | 0.010 |
Why?
|
| Glucagon | 1 | 1992 | 533 | 0.010 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 1992 | 340 | 0.010 |
Why?
|
| Potassium Channels | 1 | 1992 | 563 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1992 | 1137 | 0.010 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1994 | 1116 | 0.000 |
Why?
|
| Rats | 2 | 1994 | 24260 | 0.000 |
Why?
|
| Transplantation, Heterologous | 1 | 1994 | 2382 | 0.000 |
Why?
|
| Biocompatible Materials | 1 | 1994 | 1736 | 0.000 |
Why?
|
| Swine | 1 | 1994 | 5917 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 2866 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1992 | 5097 | 0.000 |
Why?
|
| Models, Biological | 1 | 1992 | 9583 | 0.000 |
Why?
|